Correspondence 0001193125-24-080597 from Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc.
Date: March 28, 2024 · CIK: 0001636282 · Accession: 0001193125-24-080597
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276251
Letter
Re: Spyre Therapeutics, Inc.
March 28, 2024
VIA EDGAR AND EMAIL
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Lauren Hamill and Jason Drory
Registration Statement on Form S-1
Filed March 27, 2024
File No. 333-276251
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended (the “Act”), Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-1 filed by the Company be accelerated to 4:01 p.m., Eastern Standard Time, on April 1, 2024 or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Branden Berns at (415) 393-4631.
Very truly yours,
SPYRE THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP March 28, 2024 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Lauren Hamill and Jason Drory Re: Spyre Therapeutics, Inc. Registration Statement on Form S-1 Filed March 27, 2024 File No. 333-276251 Ladies and Gentlemen: Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended (the “Act”), Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-1 filed by the Company be accelerated to 4:01 p.m., Eastern Standard Time, on April 1, 2024 or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Branden Berns at (415) 393-4631. Very truly yours, SPYRE THERAPEUTICS, INC. By: /s/ Cameron Turtle Name: Cameron Turtle Title: Chief Executive Officer cc: Scott Burrows, Spyre Therapeutics, Inc. Heidy King-Jones, Spyre Therapeutics, Inc. Ryan A. Murr, Gibson, Dunn & Crutcher LLP Branden C. Berns, Gibson, Dunn & Crutcher LLP Melanie Neary, Gibson, Dunn & Crutcher LLP